Russian billionaire to acquire South African drugmaker Ascendis Health assets

7 February 2022

merger_acquisition_deal_shutterstock_large

Russian billionaire Mikhail Fridman, together with partners, is acquiring the European assets of South African pharmaceutical manufacturer Ascendis Health (JSE: ASC). The takeover takes place as part of the recapitalization of a debt-ridden holding, reports The Pharma Letter’s local correspondent.

So far, the partners have filed a petition with the Competition Commission of the Republic of Cyprus to acquire the assets of the South African pharmaceutical holding Ascendis Health.

The main interest of bidders is related with the Cypriot-based generic drug maker Remedica, Spanish firm Farmalider, and Sun Wave Pharma, which manufactures and distributes drugs and nutritional supplements in the number of the European Union states.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK